Insights
Search Results
News Articles
6.04.26
Wilson Sonsini Practices, Attorneys Recognized in 2026 Chambers USA Guide
The 2026 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 44 geography-specific practice categories and named 87 Wilson Sonsini attorneys among the best in their fields. This year, the firm received four new practice area rankings, including in the nationwide National Security and Capital Markets: Convertible Debt categories, and three improved practice area rankings.
Client Highlights
4.08.26
Wilson Sonsini Advises Sidewinder Therapeutics on Oversubscribed $137 Million Series B Financing
On April 8, 2026, Sidewinder Therapeutics, a biopharmaceutical company pioneering the development of next-generation bispecific antibody-drug conjugates (ADCs) for the treatment of cancer, announced the closing of an oversubscribed $137 million Series B financing. The round was co-led by Frazier Life Sciences and Novartis Venture Fund, with participation from the sole Series A investor OrbiMed, as well as new investors including Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management, and Alexandria Venture Investments. Wilson Sonsini Goodrich & Rosati advised Sidewinder Therapeutics on the transaction.
Client Highlights
1.12.26
Firm Advises Mirador on Patent Matters Related to $250 Million Series B
On January 12, 2026, Mirador Therapeutics, Inc., a clinical-stage precision medicine company developing next-generation therapies for immune-mediated inflammatory and fibrotic diseases, announced it has closed a $250 million Series B financing, bringing total capital raised to more than $650 million since the company launched in March 2024. The proceeds enable Mirador to deliver proof-of-concept across all current programs and support the development of additional pipeline candidates. Wilson Sonsini Goodrich & Rosati has advised Mirador on patent matters since the company’s inception, and counseled Mirador on patent matters related to this latest transaction.
Client Highlights
1.12.26
Wilson Sonsini Advises on Juvena Therapeutics on IP Matters Related to $33.5 Million Series B
On January 12, 2026, Juvena Therapeutics, a clinical-stage biotechnology company whose AI-enabled regenerative biologics are designed to restore tissue function, announced its $33.5 million Series B. The financing round was led by Bison Ventures with participation from Eli Lilly and Company, Jefferson Life Sciences, and existing institutional backers including Mubadala Capital and Manta Ray. Wilson Sonsini Goodrich & Rosati advised Juvena on IP matters related to the transaction.
Client Highlights
12.04.25
Wilson Sonsini Advises Belite Bio on Patent Matters Related to $350 Million Public Offering of American Depositary Shares
On December 1, 2025, Belite Bio, a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, announced the pricing of an underwritten public offering at approximately $350 million. Wilson Sonsini Goodrich & Rosati has advised Belite Bio on patent matters since the company's inception, in addition to FDA regulatory, licensing, and litigation matters, and counseled Belite on patent matters related to this latest offering.
Client Highlights
11.10.25
Wilson Sonsini Advises Iambic on Oversubscribed $100 Million Financing
On November 10, 2025, Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced that it has raised approximately $100 million in an oversubscribed financing round. Wilson Sonsini Goodrich & Rosati advised Iambic on the transaction.
Client Highlights
10.28.25
Wilson Sonsini Advises Empirico on License Agreement with GSK
On October 28, 2025, GSK and Empirico, a clinical-stage biotechnology company with leading capabilities in human genetics-driven target discovery and siRNA medicines, announced that they have entered into a worldwide exclusive license agreement for EMP-012, a highly selective first- and potentially best-in-class siRNA, a type of oligonucleotide. EMP-012 addresses a novel therapeutic target and is currently in a Phase 1 trial for the treatment of chronic obstructive pulmonary disease (COPD), with the potential for expansion into other inflammatory respiratory diseases. Wilson Sonsini Goodrich & Rosati advised Empirico on the transaction.
Client Highlights
9.30.25
Wilson Sonsini Advises LuxWall on Patent Matters Related to Partnership with Saint-Gobain Glass
On September 22, 2025, Saint-Gobain Glass, a leader in flat glass for building applications, and LuxWall, the pioneer in transparent insulation technology, announced a strategic partnership to bring INSIOTMnext-generation vacuum glazing to the European market. Wilson Sonsini Goodrich & Rosati created LuxWall’s patent strategy and advised the company on patent matters related to the transaction.
Client Highlights
9.10.25
Firm Advises Belite Bio on Patent Matters Related to $275 Million Private Placement
On September 10, 2025, Belite Bio, Inc., a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, announced that it has entered into securities purchase agreements with leading healthcare investors for a private placement in public equity financing (PIPE) that is expected to result in gross proceeds of approximately $125 million, before deducting placement agent fees and estimated offering expenses, and up to an additional approximately $150 million in gross proceeds if the accompanying warrants are fully exercised for cash. Wilson Sonsini Goodrich and Rosati advised Belite Bio on patent matters related to the transaction.
Client Highlights
7.30.25
Wilson Sonsini Advises ImmunityBio on Execution of $80 Million Equity Financing
On July 25, 2025, ImmunityBio, a biotechnology company developing therapies that bolster the natural immune system to defeat cancers and infectious diseases, announced it has executed financing to provide further working capital and support its ongoing business operations. The company entered into a securities purchase agreement for a registered direct offering with two institutional investors, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of ImmunityBio that is expected to result in gross proceeds at closing of approximately $80 million before deducting placement agent fees and other offering-related expenses, subject to customary closing conditions. If fully exercised, the warrants could result in additional gross proceeds of up to approximately $96 million. Wilson Sonsini Goodrich & Rosati advised ImmunityBio on the transaction.
The Wilson Sonsini team advising ImmunityBio includes:
Corporate
Patents and Innovations
For more information, please see ImmunityBio’s press release.
Podcasts
7.22.25
Matt Bresnahan Featured on Good Medicine Podcast
Wilson Sonsini partner Matt Bresnahan is the featured guest on the latest episode of Good Medicine, a podcast hosted by Dr. David Bearss, an accomplished biopharmaceutical executive, entrepreneur, and researcher with over 30 years of experience in the life sciences industry, including as co-founder, president, and CEO of Wilson Sonsini client Halia Therapeutics. In the episode, titled “Protecting Biotech Innovation: Patent Insights with Matt Bresnahan,” Matt discusses what qualifies as patent-eligible and why biotech innovations have to walk a fine line; how the patent clock starts ticking and what it means for drug development timelines; and how the patent system is designed to push innovation toward solving unmet medical needs, benefiting patients and driving down long-term costs, among other topics.